SORAFENIB TOSYLATE | N021923 | BAYER HEALTHCARE PHARMACEUTICALS INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
| D. Del. | 2021-10-29 | Terminated 2022-02-18 | — | |
| D. Del. | 2021-07-07 | Terminated 2021-11-19 | — | |
| D. Del. | 2018-10-04 | Terminated 2018-11-14 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from Hyman, Phelps & McNamara, P.C FDA-2018-P-0878 · 6 docket documents The law firm Hyman, Phelps & McNamara, P.C., filing on behalf of a client, submitted a citizen petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA determine that Sorafenib Tosylate Tablets, 400 mg, is suitable for submission in an Abbreviated New D | Other | 2018-04-10 | Granted | Hyman, Phelps & McNamara, P.C |
Source: Regulations.gov. FDA citizen petitions matched by application number.